Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy

Table 5

Phase II studies with DON.

Number of patients	Tumor type	DON schedule	Observations	References
22	Advanced lung cancer	160 mg/m^2 days 1–3, every 21 days	4 (18.1%) had transient disease stabilization (3–12 weeks)	[60]
30	Advanced colorectal	160 mg/m^2 days 1–3, every 21 days	16 (53%) had disease stabilization (3–26 weeks)	[61]
23 (14 evaluable)	Advanced colorectal	300 mg/m^2 days 1–5 every 2 weeks; (deescalated to 200 mg)	PR 1 (7%); SD 2 (14%), 2 and 5.5 months	[62]
36	Pretreated advanced sarcoma	50 mg/m^2 days 1–5, every 28 days	No responses; median OS 4.8 months	[63]
55	Advanced, refractory malignancies	140 mg/m^2 twice weekly + PEG-PGA	Treatment delivered; 1–379 days; 1 PR and 1 SD (>12 months) in 17 colorectal pts.; 5 of 6 with lung cancer SD in the first 3 months of inclusion	[64]

PEG-PGA: PEGylated recombinant human glutaminase; PR: partial response; CR: complete response; SD: stable disease; OS: overall survival.